Por favor, use este identificador para citar o enlazar a este item:
http://hdl.handle.net/10261/62268
COMPARTIR / EXPORTAR:
SHARE CORE BASE | |
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE | |
Título: | Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: Consensus statement |
Autor: | Palumbo, Antonio; Delforge, Michel; Ludwig, Heinz; San Miguel, Jesús F. CSIC ORCID | Fecha de publicación: | 2011 | Editor: | Nature Publishing Group | Citación: | Leukemia 25: 749-760 (2011) | Resumen: | An expert panel convened to reach a consensus regarding the optimal use of lenalidomide in combination with dexamethasone (Len/Dex) in patients with relapsed or refractory multiple myeloma (RRMM). On the basis of the available evidence, the panel agreed that Len/Dex is a valid and effective treatment option for most patients with RRMM. As with other therapies, using Len/Dex at first relapse is more effective regarding response rate and durability than using it after multiple salvage therapies. Len/Dex may be beneficial regardless of patient age, disease stage and renal function, although the starting dose of lenalidomide should be adjusted for renal impairment and cytopenias. Long-term treatment until there is evidence of disease progression may be recommended at the best-tolerated doses of both lenalidomide and dexamethasone. Recommendations regarding the prevention and management of adverse events, particularly venous thromboembolism and myelosuppression, were provided on the basis of the available evidence and practical experience of panel members. Ongoing trials will provide more insight into the effects of continuous lenalidomide-based therapy in myeloma. © 2011 Macmillan Publishers Limited All rights reserved. | URI: | http://hdl.handle.net/10261/62268 | DOI: | 10.1038/leu.2011.3 | Identificadores: | doi: 10.1038/leu.2011.3 issn: 0887-6924 |
Aparece en las colecciones: | (IBMCC) Artículos |
Ficheros en este ítem:
Fichero | Descripción | Tamaño | Formato | |
---|---|---|---|---|
accesoRestringido.pdf | 15,38 kB | Adobe PDF | Visualizar/Abrir |
CORE Recommender
SCOPUSTM
Citations
103
checked on 18-abr-2024
WEB OF SCIENCETM
Citations
92
checked on 25-feb-2024
Page view(s)
332
checked on 24-abr-2024
Download(s)
95
checked on 24-abr-2024
Google ScholarTM
Check
Altmetric
Altmetric
NOTA: Los ítems de Digital.CSIC están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.